32P-post-labelling analysis of nucleobases involved in the formation of DNA adducts by antitumor 1-nitroacridines

Chemico-Biological Interactions

Volumn 103, Issue 2, 1997, Pages 131-139

  Bartoszek, Agnieszka ^a   Dackiewicz, Paweł ^a   Konopa, Jerzy ^a  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

1 Nitroacridines; 32P post labelling assay; DMA addicts; Ledakrin

Indexed keywords

9 (2 HYDROXYETHYLAMINO) 1 NITROACRIDINE; ACRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; NITRACRINE; NUCLEOTIDE; PHOSPHORUS 32; UNCLASSIFIED DRUG; 1 NITRO 9 (2' HYDROXYETHYLAMINO)ACRIDINE HYDROCHLORIDE; 1-NITRO-9-(2'-HYDROXYETHYLAMINO)ACRIDINE HYDROCHLORIDE; AMINOACRIDINE DERIVATIVE; DITHIOTHREITOL; DNA; NUCLEIC ACID SYNTHESIS INHIBITOR; PHOSPHORUS; POLYADENYLIC ACID; POLYGUANYLIC ACID; THIOL REAGENT;

ARTICLE; COVALENT BOND; DNA ADDUCT; ISOTOPE LABELING; NONHUMAN; ANIMAL; BIOSYNTHESIS; CATTLE; COMPARATIVE STUDY; DNA FINGERPRINTING; DRUG EFFECT; METABOLISM;

AMINOACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; DITHIOTHREITOL; DNA; DNA ADDUCTS; DNA FINGERPRINTING; ISOTOPE LABELING; NITRACRINE; NUCLEIC ACID SYNTHESIS INHIBITORS; PHOSPHORUS RADIOISOTOPES; POLY A; POLY G; SULFHYDRYL REAGENTS;

EID: 0031588541     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(96)03753-2     Document Type: Review

References (12)

1. [1] J. Konopa, A. Ledóchowski, A. Matuszkiewicz and E. Jereczek-Morawska, In vitro studies on the cytotoxic properties of 9-aminoacridine derivatives, Neoplasma, 16 (1969) 171-179.
2. [2] M. Hrabowska, Z. Mazerska, J. Paradziej-Łukowicz, K. Onoszko and A. Ledóchowski, Antitumor activity of 1-nitro-9-aminoacridine derivatives, Drug Res., 32 (1982) 1013-1016.
3. [3] K. Pawlak, J.W. Pawlak and J. Konopa, Cytotoxic and antitumor activity of 1-nitroacridines as an aftereffect of their interstrand DNA cross-linking, Cancer Res. 44 (1984) 4289-4296.
4. 32P-Post-labelling analysis of DNA adduct formation by antitumor drug nitracrine (Ledakrin) and other nitroacridines in different biological systems, Biochem. Pharmacol., 38 (1989) 1301-1312.
5. [5] M. Gniazdowski, E. Ciesielska and L. Szmigiero, Some properties of the irreversible complexes of nitracrine (Ledakrin, C-283) with polynucleotides, Chem.-Biol. Interact., 34 (1981) 355-366.
6. 32P-Post-labeling analysis of non-radioactive aromatic carcinogen-DNA adducts, Carcinogenesis, 3 (1982) 1081-1092.
7. 32P-Post-labeling test for covalent DNA binding of chemicals in vivo: application to a variety of aromatic carcinogens and methylating agents, Carcinogenesis, 5 (1984) 231-243.
8. [8] K. Gorlewska, Z. Mazerska and J. Konopa, Metabolic reaction pathway of the antitumor drug Ledakrin (Nitracrine): studies with the use of model systems. Exp. Toxic. Pathol. 48 (1996) 155-160.
9. 32P-post-labeling analysis, Mutat. Res., 152 (1985) 85-96.
10. 32P-postlabeling method, Jpn. J. Cancer Res., 85 (1994) 113-117.
11. 32P-post-labelling of 7-methyl-dGMP ring-opened 7-methyl-dGMP and platinated dGpdG, Chem.-Biol. Interact., 74 (1990) 45-54.
12. [12] Bea Singer, In vivo formation and persistence of modified nucleotides resulting from alkylating agents, Environ. Health. Perspect. 62 (1985) 41-48.